Morbidity, Long-term Side Effects and Quality of Life in Germ-cell Tumor Long Survivors Treated with High-dose Chemotherapy and Autologous Stem Cell Transplant

Inclusion Criteria: * Age ≥ 18 years at diagnosis * Treated between 1990 and 2015 * Histologically confirmed diagnosis of germ cell tumor (or high level serum tumor marker-based) and: Treated for relapse with high-dose of chemotherapy (HDCT) with autologous transplant at Gustave Roussy and relapse-free. Or Treated by orchiectomy only and no evidence of relapse after a minimum of 3 years. Or Good or intermediate prognosis metastatic disease according to the IGCCCG, treated by first line cisplatin-based chemotherapy at Gustave Roussy (and surgery of residual masses if needed), with no evidence of relapse. * Ability to comply with the protocol procedures * Patient affiliated to a social security system or beneficiary of the same. 6-Who have signed a written informed consent form prior to any study specific procedure. Exclusion Criteria: * Diagnosis of second malignancy * Any other serious or unstable illness, or medical, social, or psychological condition, that could jeopardize the safety of the subject and/or his compliance with study procedures, or may interfere with the subject's participation in the study or evaluation of the study results. * Patient under guardianship or deprived of his/her liberty by a judicial or administrative decision, or incapable of giving his/her consent.